Although ABT-263 is a highly specific senolytic agent, it causes transient thrombocytopenia and neutropenia in patients [70]; this results from its inhibitory effect on Bcl-xL, which is important for platelet survival [71, 72]. Here, BCL2L1 is linked to Thrombocytopenia.